Matteo Levisetti - 17 Jan 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Medical Officer
Signature
/s/ Matteo Levisetti by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
17 Jan 2023
Net transactions value
$0
Form type
4
Filing time
19 Jan 2023, 15:02:38 UTC
Next filing
25 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +110,000 $0.000000 110,000 17 Jan 2023 Common Stock 110,000 $3.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in eight equal semi-annual installments beginning on 7/17/2023